Anzeige
Mehr »
Login
Mittwoch, 22.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Mit dieser Aktie könntest Du von der Cannabis-Legalisierungswelle profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D4G4 | ISIN: US13471N3008 | Ticker-Symbol: CF5
NASDAQ
21.05.24
22:00 Uhr
2,470 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CAN-FITE BIOPHARMA LTD ADR Chart 1 Jahr
5-Tage-Chart
CAN-FITE BIOPHARMA LTD ADR 5-Tage-Chart

Aktuelle News zur CAN-FITE BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.05.Can-Fite BioPharma Ltd.: Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study286Can-Fite has received agreement from both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) on the current pivotal Phase 3 clinical study Can-Fite BioPharma Ltd. (NYSE...
► Artikel lesen
13.05.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer-
10.05.Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV309ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money...
► Artikel lesen
09.05.Can-Fite stock up on FDA IND clearance for namodenoson to treat MASH patients in mid-stage study1
06.05.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer2
06.05.Can-Fite BioPharma Ltd.: Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602235Patent has already been issued in other major markets including the U.S. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary...
► Artikel lesen
25.04.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer-
15.04.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer2
05.04.Can-Fite BioPharma Ltd. - S-8, Securities to be offered to employees in employee benefit plans2
03.04.Can-Fite BioPharma Ltd.: Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients298Namodenoson demonstrated anti-fibrosis, anti-steatosis and anti-inflammatory effects in former Phase IIa study Patient enrolment for Phase IIb study is ongoing in Europe and Israel Can-Fite...
► Artikel lesen
01.04.Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV165Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel...
► Artikel lesen
28.03.Can-Fite BioPharma Ltd. - 20-F, Annual and transition report of foreign private issuers1
28.03.Can Fite Biofarma: Q4 Earnings Insights1
28.03.Can-Fite Biopharma GAAP EPS of -$0.01, revenue of $0.74M2
28.03.Can-Fite BioPharma Ltd.: Can-Fite Reports 2023 Financial Results and Clinical Update273Ewopharma acquired marketing rights for namodenoson in the treatment of pancreatic carcinoma Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline...
► Artikel lesen
28.03.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer2
28.03.Can-Fite Reports 2023 Financial Results and Clinical Update62RAMAT GAN, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological...
► Artikel lesen
11.03.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer2
28.02.Can-Fite secures Canadian patent for liver disease drug2
28.02.Can-Fite BioPharma Ltd. - 6-K, Report of foreign issuer1
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1